News

The Michael J. Fox Foundation (MJFF) has awarded a total of $8.5 million to research teams at AC Immune, Mass General Brigham, and Merck to develop a way to detect the protein alpha-synuclein in the brains of people living with Parkinson’s disease. The three…

Parkinson’s UK is asking patients and others in the community to take part in a survey about research participation in the wake of the COVID-19 pandemic, and possible adaptations for study environments. The goal is to help researchers make sure that face-to-face studies restart in ways that are safe,…

AC Immune anticipates advancing ACI-12589, its novel alpha-synuclein positron emission tomography (PET) tracer for Parkinson’s disease diagnosis, to clinical development in the last quarter of this year. Based on positive new data, the company made the announcement during an oral presentation at the virtual Alzheimer’s Association International…

Axial Biotherapeutics announced a $440,000 grant from the Michael J. Fox Foundation for Parkinson’s Research to support its efforts to develop a model that can mimic the nervous system of the gastrointestinal tract, and help in evaluating potential Parkinson’s disease treatments. Though Parkinson’s is primarily considered a neurodegenerative disorder,…

The levels of two types of fatty molecules — anandamide and glucocerebroside — are significantly altered in people with Parkinson’s disease, and associate with sensory nerve damage and chronic pain, a study reported. These findings suggest that patients with sensory problems and pain may benefit from available…

Regular use of aspirin or ibuprofen could lower the risk of Parkinson’s disease associated with mutations in the LRRK2 gene, a new study suggests. The study, “Nonsteroidal Anti‐Inflammatory Use and LRRK2 Parkinson’s Disease Penetrance,” was published in Movement Disorders. Mutations in LRRK2 are one…

The idea that a simple over-the-counter supplement called mannitol might alleviate the symptoms of Parkinson’s disease has been gaining traction since at least 2013.  Now, a documentary released July 29 called “My Disease Our Revolution” is bringing more attention to the supplement’s potential in Parkinson’s.

A documentary premiering July 29 on Israel’s satellite TV service provider, yes, highlights what one Parkinson’s disease patient was able to achieve when he set out to advocate for himself and other patients.  In collaboration with Nisan Katz and Nir Kafri…

The U.S. Food and Drug Administration (FDA) has approved a new app developed by Abbott, called the Patient Controller app, which will allow patients with chronic neurological conditions to manage personalized therapy regimens using compatible smartphones. The Patient Controller app, which is compatible with Apple’s operating system iOS, synchronizes…

Loss of the sense of smell is associated with longer disease duration in Parkinson’s, suggesting this sense increasingly fails as the disease progresses. Its decline may be a clinically useful biomarker of Parkinson’s progression and severity, the study’s researchers said. These findings were in “Association between olfactory…